- Human（1）
No data
- His Tag & Avi Tag（1）
No data
- HEK293（1）
No data
- Biotin-labeled（1）
No data
- RUO（1）
No data
- No（1）
No data
- 25ug/$125.00
- 200ug/$700.00
No data
| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| MR1 & B2M | Biotinylated Human MR1&B2M Complex Protein (MALS verified) |  Human | HEK293 | MALSSDS-PAGE | $125.00 25ug |   |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Nidanilimab | CAN-04 | Phase 2 Clinical | Lund University Foundation | Solid tumours; Biliary Tract Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| CCTx-001 | CCTx-001 | Phase 2 Clinical | Advesya SAS | Leukemia, Myeloid, Acute | Details |
| SAR-445399 | SAR-445399 | Phase 1 Clinical | Sanofi | Inflammation | Details |
| GSK3903371 | GSK3903371 | Clinical | Glaxosmithkline Plc | Neoplasms | Details |
